Premium
BiomX Inc (PHGE)
AMEX
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflamma... BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Show more
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now...
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1824 | 33.3089846603 | 0.5476 | 0.789 | 0.52 | 104678 | 0.67958453 | CS |
| 4 | 0.0065 | 0.898410504492 | 0.7235 | 0.8122 | 0.48 | 183923 | 0.72166948 | CS |
| 12 | -0.38 | -34.2342342342 | 1.11 | 1.15 | 0.48 | 86086 | 0.79461548 | CS |
| 26 | -3.32 | -81.975308642 | 4.05 | 4.425 | 0.48 | 186011 | 1.827008 | CS |
| 52 | -2.315 | -76.026272578 | 3.045 | 8.55 | 0.48 | 806047 | 5.66694702 | CS |
| 156 | -16.07 | -95.6547619048 | 16.8 | 21.4 | 0.48 | 383608 | 5.50602376 | CS |
| 260 | -79.27 | -99.0875 | 80 | 110.5 | 0.48 | 244883 | 8.63519212 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
